RE
REGN
Quarter ended Sep 30, 2025 · FY2025 Q3

Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Sep 30, 2025

Revenue increased in the quarter. Both on a sequential and year-over-year basis, revenue was higher.

Key takeaway

Quarter ended Sep 30, 2025 · FY2025 Q3

Revenue increased in the quarter. Both on a sequential and year-over-year basis, revenue was higher.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$3.8B

Revenue reported for this quarter.

Quarter-over-quarter

+2.1%

Change from the immediately preceding quarter.

Year-over-year

+0.9%

Change from the comparable year-ago quarter.

Trailing four quarters

$14.2B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Dec 31, 2024$3.8B+10.3%
Mar 31, 2025$3B-3.7%
Jun 30, 2025$3.7B+3.6%
Sep 30, 2025$3.8B+0.9%

Revenue performance

The reported revenue reflects growth compared to the immediately preceding quarter and the same quarter one year earlier.

Quarterly comparison

The sequential increase was larger than the year-over-year increase, suggesting that recent performance is stronger relative to the prior quarter than to the same period last year.

What to watch

The year-over-year growth rate is smaller than the sequential growth rate, which may warrant monitoring of the annual trend.

Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Sep 30, 2025